Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.
Ménard C, Navarro-Domenech I, Liu ZA, Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin MC, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J, Chung P. Ménard C, et al. Among authors: weersink r. Front Oncol. 2022 Aug 26;12:971344. doi: 10.3389/fonc.2022.971344. eCollection 2022. Front Oncol. 2022. PMID: 36091157 Free PMC article.
Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
Sanmamed N, Adleman J, Berlin A, Borg J, Lao B, Weersink R, Simeonov A, Rink A, Beiki-Ardakani A, Menard C, Chung P, Helou J. Sanmamed N, et al. Among authors: weersink r. Brachytherapy. 2023 Jan-Feb;22(1):58-65. doi: 10.1016/j.brachy.2022.08.015. Epub 2022 Nov 19. Brachytherapy. 2023. PMID: 36414526 Clinical Trial.
Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.
Ménard C, Navarro-Domenech I, Liu ZA, Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin MC, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J, Chung P. Ménard C, et al. Among authors: weersink r. Front Oncol. 2022 Nov 17;12:1084708. doi: 10.3389/fonc.2022.1084708. eCollection 2022. Front Oncol. 2022. PMID: 36465337 Free PMC article.
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy.
Scott AA, Weersink M, Liu ZA, Milosevic M, Croke J, Fyles A, Lukovic J, Rink A, Beiki-Ardakani A, Borg J, Xie J, Chan K, Ballantyne H, Skliarenko J, Conway JL, Gladwish A, Weersink RA, Han K. Scott AA, et al. Brachytherapy. 2023 Mar-Apr;22(2):146-156. doi: 10.1016/j.brachy.2022.11.005. Epub 2022 Dec 15. Brachytherapy. 2023. PMID: 36528475
92 results